European Autoimmune Disease Diagnostics Market Industry: Market Size & Forecast 2026

Autoimmune disease diagnostics involve laboratory tests used to identify and monitor over 80 recognized autoimmune conditions in which the immune system attacks the body's own tissues. The market encompasses a wide range of products, including immunoassay analyzers, ELISA kits, indirect immunofluorescence assays, and multiplex testing platforms that detect specific autoantibodies such as ANA, anti-CCP, and anti-dsDNA.

• •Global market estimates for 2025 vary across research firms, with valuations ranging from approximately $3.6 billion to $7.4 billion
• •Europe constitutes one of the largest regional markets, with country-level estimates ranging from about $1.46 billion to $2.76 billion in 2025 depending on scope
• •Growth projections through the early 2030s generally fall in the 5.6% to 9.5% annual range, reflecting differing methodologies and geographic coverage

The primary forces propelling market growth include the rising global prevalence of autoimmune diseases, an aging demographic profile, and expanding healthcare access in emerging markets. Greater physician awareness, improved diagnostic guidelines, and advances in biomarker research are enabling earlier and more accurate detection of autoimmune conditions, which contributes to higher testing volumes.

• •Approximately 5% to 8% of the global population is affected by some form of autoimmune disease, a figure that has been rising in recent decades
• •Advances in multiplex testing and automation allow laboratories to process more samples efficiently while improving diagnostic accuracy
• •Growing government and private investment in healthcare infrastructure, particularly in Asia-Pacific and Eastern Europe, is expanding access to diagnostic services

The market is commonly segmented by product type, including assay kits and reagents, analytical instruments, and software and services, as well as by disease indication, test type, and end-user. Geographically, North America and Europe together account for the largest combined share, with Europe often cited as holding roughly a quarter of global market value, while Asia-Pacific is growing at a faster pace.

• •Rheumatoid arthritis, systemic lupus erythematosus, and thyroid autoimmune disorders represent some of the most widely tested indications
• •Hospitals and clinical laboratories are the dominant end-users, with specialized autoimmune testing centers playing an important secondary role
• •Within Europe, Western European nations including Germany, France, and the United Kingdom typically account for a significant portion of regional testing volume

What are the recent trends and outlook?

Emerging trends shaping the market include the adoption of personalized medicine approaches, point-of-care testing expansion, and the growing role of artificial intelligence in interpreting complex diagnostic panels. The convergence of genomic research and autoimmunity is expected to yield new biomarkers, while home-based and at-home sample collection services may reshape testing workflows over the forecast period.

• •Multiplex testing platforms capable of detecting multiple autoantibodies simultaneously from a single sample are gaining adoption in clinical laboratories
• •Advances in proteomics and next-generation sequencing are expected to expand the range of available autoimmune biomarkers beyond current autoantibody panels
• •Consolidation among clinical laboratory networks and the adoption of standardized testing protocols are influencing how diagnostic products reach end-users across healthcare systems